ClinicalTrials.gg
TerminatedNCT04652700Impower-024Updated May 5, 2026Results posted

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

A Phase 3 interventional study of ISL and FTC/TDF in HIV Preexposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Terminated at 25 sites in 7 countries. Open to male participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Why this study was terminated
Voluntarily terminated due to benefit/risk assessment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
16 Years and older
Sex
Male
01

Study summary

The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with 48 or 96 weeks of treatment and a minimum follow-up of 42 days.

Read the detailed description

Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program, dosing of blinded study intervention was halted on 13-Dec-2021. Blinded assessments conducted prior to then are designated as Study Part 1. During Study Part 2, participants from Part 1 were switched to PrEP therapy with emtricitabine/tenofovir disoproxil (FTC/TDF) or emtricitabine/tenofovir alafenamide (FTC/TAF) while continuing in the study, but participants, investigators, and Sponsor personnel remained blinded to the Part 1 treatment. In Part 3, participants, investigators, and all Sponsor personnel are unblinded to participant's original randomized intervention group, and participants may continue to receive unblinded FTC/TDF or FTC/TAF.

02

Conditions studied

  • HIV Preexposure Prophylaxis

Keywords

  • Preexposure prophylaxis (PrEP)
  • Prevention
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed (HIV) uninfected based on negative HIV-1/HIV-2 test result before randomization
  • Is sexually active with male or transgender women (TGW) partners defined as having anal sexual intercourse with a man or TGW at least once in the past month
  • Is at high risk for sexually acquiring HIV-1 infection based on self-report of at least 1 of the following: a) Condomless receptive anal intercourse in the 6 months prior to screening occurring outside a mutually monogamous HIV seronegative concordant relationship b) More than 5 partners (anal intercourse) in the 6 months prior to screening c) Any unprescribed stimulant drug use in the 6 months prior to screening d) Rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening
  • Participants 16 or 17 years of age must weigh ≥35 kg. Enrollment for 16- to 17-year-old participants will begin only after completion of the Sentinel Cohort IA and review of IA results by the external data monitoring committee (eDMC)
  • Has no plans to relocate or travel away from the site for ≥4 consecutive weeks during study participation

Exclusion criteria

Exclusion Criteria:

  • Has or other to any component of the study interventions as determined by the investigator
  • Has chronic infection or past HBV infection which could indicate risk for Hepatitis B reactivation
  • Has known current or chronic history of liver disease or known hepatic or biliary abnormalities, unless the participant has stable liver function tests and no evidence of hepatic synthetic dysfunction
  • Has a history of within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer or in situ anal cancers
  • Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to enroll
  • Has taken cabotegravir, lenacapavir, or any other long-acting prevention product at any time
  • Is currently receiving or is anticipated to require any prohibited therapies outlined in the study from 30 days prior to Day 1 through the duration of the study
  • Is currently participating in or has participated in an interventional or prevention clinical study with an compound or device, within 30 days prior to Day 1 through the duration of the study
  • Has exclusionary laboratory values within 45 days prior to Day 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
494 participants (actual)

Study arms

  • Experimental
    Islatravir (ISL) Once Monthly (QM) Group

    Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.

    Drug: ISL · Drug: Placebo to FTC/TDF · Drug: Placebo to FTC/TAF

  • Active comparator
    FTC/TDF or FTC/TAF QD Group

    Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.

    Drug: FTC/TDF · Drug: FTC/TAF · Drug: Placebo to ISL

Interventions

  • DrugISL

    ISL 60 mg tablet, QM, orally for up to 24 months

    Also known as: MK-8591

  • DrugFTC/TDF

    Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months

    Also known as: Truvada, Emtricitabine/Tenofovir Disoproxil Fumarate

  • DrugFTC/TAF

    Drug page: Emtricitabine tenofovir alafenamide

    Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months

    Also known as: Descovy, Emtricitabine/Tenofovir Alafenamide

  • DrugPlacebo to ISL

    Placebo ISL 0 mg tablets QM, orally for up to 24 months.

  • DrugPlacebo to FTC/TDF

    Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months

  • DrugPlacebo to FTC/TAF

    Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

    Time frame: Up to approximately 10.5 months

  2. Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

    Time frame: Up to approximately 9 months

Secondary outcomes

  1. Number of Participants With Confirmed HIV-1 Infection

    The number of participants with confirmed HIV-1 infections during the blinded treatment period is presented.

    Time frame: Up to approximately 10.5 months

07

Results

Posted Dec 11, 2024

Participant flow

Part 1: Blinded Study Medication
Participant flow — Part 1: Blinded Study Medication
MilestonePart 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAF
Started328166
Completed00
Not completed328166
Withdrew: Adverse event10
Withdrew: Lost to follow-up72
Withdrew: Multiple reasons (primarily discontinuation of blinded treatment)308160
Withdrew: Withdrawal by subject124
Parts 2 and 3: Open-Label FTC TDF or TAF
Participant flow — Parts 2 and 3: Open-Label FTC TDF or TAF
MilestonePart 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAF
Started306154
Completed00
Not completed306154
Withdrew: Lost to follow-up349
Withdrew: Not reported61
Withdrew: Physician decision02
Withdrew: Study terminated by sponsor227119
Withdrew: Withdrawal by subject3923

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

Time frame:
Up to approximately 10.5 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment
ParticipantsPart 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAF
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment211128
PrimaryNumber of Participants Who Discontinued From Blinded Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

Time frame:
Up to approximately 9 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE
ParticipantsPart 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAF
Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE10
SecondaryNumber of Participants With Confirmed HIV-1 Infection

The number of participants with confirmed HIV-1 infections during the blinded treatment period is presented.

Time frame:
Up to approximately 10.5 months
Reported as:
Count of participants · Participants
Number of Participants With Confirmed HIV-1 Infection
ParticipantsPart 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAF
Number of Participants With Confirmed HIV-1 Infection00

Adverse events

Collected over Entire Study: Blinded Treatment (Part 1) + Open-Label Standard-of-Care Treatment (Parts 2 & 3) [Up to approximately 26 months]. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: ISL0/328 (0%)6/328 (1.8%)120/328 (36.6%)
Parts 2 & 3: Open-label PrEP (ISL in Part 1)0/306 (0%)18/306 (5.9%)230/306 (75.2%)
Part 1: FTC/TDF or FTC/TAF0/166 (0%)1/166 (0.6%)88/166 (53%)
Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)0/154 (0%)5/154 (3.2%)104/154 (67.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart 1: ISLParts 2 & 3: Open-label PrEP (ISL in Part 1)Part 1: FTC/TDF or FTC/TAFParts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)
COVID-19Infections and infestations1/3288/3061/1661/154
AppendicitisInfections and infestations1/3280/3060/1662/154
Upper respiratory tract infectionInfections and infestations0/3280/3060/1661/154
Suicidal ideationPsychiatric disorders0/3280/3060/1661/154
CellulitisInfections and infestations0/3281/3060/1660/154
Dengue feverInfections and infestations0/3281/3060/1660/154
Peritonsillar abscessInfections and infestations0/3281/3060/1660/154
Pyelonephritis acuteInfections and infestations0/3281/3060/1660/154
Viral infectionInfections and infestations0/3281/3060/1660/154
Alcohol poisoningInjury, poisoning and procedural complications0/3281/3060/1660/154
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPart 1: ISLParts 2 & 3: Open-label PrEP (ISL in Part 1)Part 1: FTC/TDF or FTC/TAFParts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)
COVID-19Infections and infestations35/32869/30621/16637/154
Proctitis chlamydialInfections and infestations20/32865/30614/16627/154
Proctitis gonococcalInfections and infestations13/32851/30615/16630/154
Oropharyngeal gonococcal infectionInfections and infestations16/32841/30611/16624/154
Upper respiratory tract infectionInfections and infestations10/32831/3068/16617/154
SyphilisInfections and infestations10/32819/3067/16615/154
InfluenzaInfections and infestations4/32814/3066/16614/154
NasopharyngitisInfections and infestations14/32827/3067/16611/154
CD4 lymphocytes decreasedInvestigations1/32824/3063/1666/154
DiarrhoeaGastrointestinal disorders19/32814/3069/16611/154

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAFTotal
Mean29.6 ± 9.629.5 ± 9.229.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAFTotal
Female000
Male328166494
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAFTotal
Hispanic or Latino11151162
Not Hispanic or Latino214111325
Unknown or Not Reported347
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAFParts 1 to 3: FTC/TDF or FTC/TAFTotal
American Indian or Alaska Native202
Asian7031101
Native Hawaiian or Other Pacific Islander202
Black or African American8341124
White13571206
More than one race352055
Unknown or Not Reported134
08

Study locations

25 sites
  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0007)
    Birmingham, Alabama 35222, United States
  • UCLA Center for Clinical AIDS Research and Education ( Site 0011)
    Los Angeles, California 90035, United States
  • Global Research Institute ( Site 0031)
    Los Angeles, California 90036, United States
  • Bridge HIV - San Francisco Department of Public Health ( Site 0003)
    San Francisco, California 94102, United States
  • The GW Medical Faculty Associates-Medicine ( Site 0033)
    Washington D.C., District of Columbia 20037, United States
  • Midway Immunology and Research Center ( Site 0014)
    Ft. Pierce, Florida 34982, United States
  • University of Miami Miller School of Medicine-Infectious Disease ( Site 0029)
    Miami, Florida 33136, United States
  • Orlando Immunology Center ( Site 0010)
    Orlando, Florida 32803, United States
  • Ponce De Leon Center Grady Health ( Site 0032)
    Atlanta, Georgia 30308, United States
  • Howard Brown Health Center ( Site 0004)
    Chicago, Illinois 60613, United States
  • The University of Mississippi Medical Center ( Site 0012)
    Jackson, Mississippi 39216, United States
  • Rutgers New Jersey Medical School-Clinical Research Center ( Site 0017)
    Newark, New Jersey 07103, United States
  • The University of North Carolina at Chapel Hill ( Site 0019)
    Chapel Hill, North Carolina 27599, United States
  • Central Texas Clinical Research ( Site 0002)
    Austin, Texas 78705, United States
  • The Crofoot Research Center ( Site 0025)
    Houston, Texas 77098, United States
  • Centro de Referência e Treinamento DST/AIDS ( Site 0351)
    São Paulo, 04121-000, Brazil
  • Hôpital Saint-Louis-Infectious Diseases and tropical diseases ( Site 0151)
    Paris, Île-de-France Region 75010, France
  • Center Hospital of the National Center for Global Health and Medicine ( Site 0101)
    Shinjyuku-ku, Tokyo 162-8655, Japan
  • Via Libre ( Site 0404)
    Lima, 15001, Peru
  • Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0203)
    Johannesburg, Gauteng 1864, South Africa
  • Wits Reproductive Health and HIV Institute (WRHI)-Research Center ( Site 0201)
    Johannesburg, Gauteng 2000, South Africa
  • Desmond Tutu HIV Foundation ( Site 0202)
    Cape Town, Western Cape 7925, South Africa
  • Chulalongkorn University-Pediatrics ( Site 0051)
    Bangkok, Bangkok 10330, Thailand
  • HIV Netherlands Australia Thailand Research Collaboration ( Site 0056)
    Bangkok, Bangkok 10330, Thailand
  • Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 0052
    Chiang Mai, 50200, Thailand
09

References and documents

Publications

  • Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez Madruga J, Liegeon G, Panchia R, Supparatpinyo K, Avihingsanon A, Creticos C, Swaminathan S, Doblecki-Lewis S, Rodriguez J, Siegel M, Oka S, Puthanakit T, Grinsztejn B, Sanders EJ, Lama JR, Lombaard J, Ndlovu N, Hwang P, Du J, Jackson B, Homony B, Evans B, Sklar P, Robertson MN, Plank RM. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093/cid/ciag171. Online ahead of print. PubMed 41830344 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Aug 2023, 28 months.

Results were first posted in Dec 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 3, 2020
StartActual
Mar 15, 2021
Primary completionActual
Aug 4, 2023
CompletionActual
Aug 4, 2023
Results first posted
Dec 11, 2024
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04652700
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Mar 15, 2021
Primary completion
Aug 4, 2023
Completion
Aug 4, 2023
Results posted
Dec 11, 2024
Last update
May 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion